gdc
PSS Guide 2023
Breast CancerFinancial Support

Drugs for Breast Cancer

Find financial assistance programs available for breast cancer drugs.

Abraxane (paclitaxel protein-bound particles; albumin-bound)

Drug company: Bristol Myers Squibb
800-861-0048

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Abraxane:

BMS Oncology Co-Pay Assistance Program

Bristol Myers Squibb Patient Assistance Foundation

Afinitor (everolimus) Tablets

Drug company: Novartis
800-282-7630

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Afinitor:

Novartis Oncology Universal Co-Pay Program

Novartis Patient Assistance Foundation

Arimidex (anastrozole) Tablets

Drug company: ANI Pharmaceuticals
855-250-2483

ANI Pharmaceuticals offers 1 financial assistance program for patients who have been prescribed Arimidex:

Arimidex Patient Direct Program

Aromasin (exemestane) Tablets

Drug company: Pfizer
877-744-5675

Pfizer Oncology Together offers 1 financial assistance program for patients using Aromasin:

Pfizer Patient Assistance Program

Ellence (epirubicin hydrochloride) Injection

Drug company: Pfizer
877-744-5675

Pfizer Oncology Together offers 1 financial assistance program for patients using Ellence:

Pfizer Patient Assistance Program

Enhertu (fam-trastuzumab) Injection

Drug company: Daiichi Sankyo/AstraZeneca
833-364-3788

Daiichi Sankyo and AstraZeneca offer 2 patient assistance programs for patients who have been prescribed Enhertu:

Enhertu Patient Savings Program

Enhertu Patient Assistance Program

Fareston (toremifene citrate) Tablets

Drug company: Kyowa Kirin
844-214-3442

Kyowa Kirin, through Patient Rx Solutions, offers 2 financial assistance programs for patients using Fareston:

Fareston Copay Assistance Card Program

Fareston Patient Assistance Program

Faslodex (fulvestrant)

Drug company: AstraZeneca
844-275-2360

AstraZeneca Access 360 offers 2 financial assistance programs for patients using Faslodex:

FASLODEX Co-pay Savings Program

AZ&Me Prescription Savings Program

Halaven (eribulin mesylate)

Drug company: Eisai
866-613-4724

Eisai offers 2 financial assistance programs for patients using Halaven:

Halaven $0 Co-Pay Program

Halaven Patient Assistance Program

Herceptin (trastuzumab)

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients using Herceptin:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Herceptin Hylecta:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Ibrance (palbociclib) Capsules/Tablets

Drug company: Pfizer
844-942-7262

Pfizer Oncology Together offers 2 financial assistance programs for patients using Ibrance:

Pfizer Oncology Together Co-Pay Savings Program

Pfizer Patient Assistance Program

Ixempra (ixabepilone)

Drug company: R-Pharm US
855-991-7277

R-Pharm US offers 1 financial assistance program for patients using Ixempra:

R-Pharm US Access + Support Program

Kadcyla (ado-trastuzumab emtansine)

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Kadcyla:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Kanjinti (trastuzumab-anns) Injection

Drug company: Amgen
888-427-7478

Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Kanjinti:

Amgen FIRST STEP Co-Pay Program

Amgen Safety Net Foundation

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Merck offers 2 financial assistance programs for patients who have been prescribed Keytruda:

Merck Co-pay Assistance Program

Merck Patient Assistance Program

Kisqali (ribociclib) Tablets

Drug company: Novartis
800-282-7630

Novartis Patient Assistance NOW Oncology offers 4 financial assistance programs for patients using Kisqali:

Kisqali Free Treatment Voucher

Kisqali 5-Treatment Cycle Access Program

Novartis Oncology Universal Co-pay Program

Novartis Patient Assistance Foundation

Lynparza (olaparib) Capsules/Tablets

Drug company: AstraZeneca
Phone: 844-275-2360

AstraZeneca offers 2 financial assistance programs for patients using Lynparza:

Lynparza Co-pay Savings Program

AZ&Me Prescription Savings Program

Margenza (margetuximab-cmkb) Injection

Drug company: MacroGenics
Phone: 844-633-6469

MacroGenics, through Margenza Access Support, offers 2 financial assistance programs for patients using Margenza:

Margenza Copay Assistance Program

Margenza Patient Assistance Program

Nerlynx (neratinib) Tablets

Drug company: Puma Biotechnology
855-816-5421

Puma Biotechnology offers 3 financial assistance programs for patients using Nerlynx:

Puma Patient Lynx Co-Pay Savings Program

Nerlynx Patient Assistance Program

Nerlynx Quick Start Program

Ogivri (trastuzumab-dkst) Injection

Drug company: Mylan
833-695-2623

Mylan, through Viatris Advocate, offers 2 financial assistance programs for patients who have been prescribed Ogivri:

Mylan Advocate Co-Pay Assistance Program

Mylan Advocate Patient Assistance

Ontruzant (trastuzumab-dttb) for Injection

Drug company: Organon
844-326-2986

Organon Access Program offers 2 financial assistance programs for patients using Ontruzant:

Organon Co-Pay Assistance Program

Organon Patient Assistance Program

Perjeta (pertuzumab)

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients using Perjeta:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial support programs for patients who have been prescribed Phesgo:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Piqray (alpelisib) Tablets

Drug company: Novartis
800-282-7630

Novartis Patient Assistance NOW Oncology offers 3 financial assistance programs for patients who have been prescribed Piqray:

Novartis Oncology Universal Co-pay Program

Free Trial Program and Access Program

Novartis Patient Assistance Foundation

Talzenna (talazoparib) Capsules

Drug company: Pfizer
877-744-5675

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Talzenna:

Pfizer Oncology Together Co-Pay Savings Card

Pfizer Patient Assistance Program

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients who have been prescribed Tecentriq:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Trazimera (trastuzumab-qyyp)

Drug company: Pfizer
877-744-5675

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Trazimera:

Pfizer Oncology Together Co-Pay Savings Program

Pfizer Patient Assistance Program

Trodelvy (sacituzumab govitecan-hziy) Injection

Drug company: Gilead
844-876-3358

Gilead, through Trodelvy Access Support, offers 2 financial assistance programs for patients who have been prescribed Trodelvy:

Trodelvy Savings Program

Gilead Patient Assistance Program

Tukysa (tucatinib) Tablets

Drug company: Seagen
855-473-2873

Seagen Secure offers 2 financial assistance programs for patients who have been prescribed Tukysa:

Commercial Out-of-Pocket Assistance Program

Patient Assistance Program

Tykerb (lapatinib) Tablets

Drug company: Novartis
800-282-7630

Novartis Patient Assistance NOW Oncology offers 2 financial assistance programs for patients using Tykerb:

Novartis Oncology Universal Co-pay Program

Novartis Patient Assistance Foundation

Verzenio (abemaciclib) Tablets

Drug company: Eli Lilly
844-837-9364

Lilly Oncology offers 2 financial assistance programs for patients who have been prescribed Verzenio:

Verzenio Continuous Care Program

Verzenio Savings Card

Xeloda (capecitabine) Tablets

Drug company: Genentech
866-422-2377

Genentech Oncology offers 1 financial support assistance program for patients who have been prescribed Xeloda:

Genentech Patient Foundation

Zoladex (goserelin) Implant

Drug company: TerSera Therapeutics
855-686-8725

TerSera Therapeutics offers 2 financial assistance programs for patients who have been prescribed Zoladex:

Zoladex Copay Card

Zoladex Patient Assistance Program

Table. Drugs Prescribed for Breast Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Arimidex (anastrozole) Tablets
  • Drug company
  • ANI Pharmaceuticals
  • Indications
  • Postmenopausal, HR-positive early breast cancer

    First-line treatment of postmenopausal HR-positive or HR-unknown, locally advanced or metastatic breast cancer

    Second-line treatment of postmenopausal advanced breast cancer after Nolvadex or Soltamox therapy
  • Patient support services
  • Arimidex Patient Direct Program
    855-250-2483

    Drug name (generic name)
  • Aromasin (exemestane) Tablets
  • Drug company
  • Pfizer
  • Indications
  • Postmenopausal ER-positive early breast cancer

    Postmenopausal advanced breast cancer, after Nolvadex or Soltamox therapy
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Ellence (epirubicin hydrochloride) Injection
  • Drug company
  • Pfizer
  • Indications
  • Axillary node tumor, after resection of primary breast cancer
  • Patient support services
  • Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Enhertu (fam-trastuzumab) Injection
  • Drug company
  • Daiichi Sankyo and AstraZeneca
  • Indications
  • Treatment of adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ ISH‑) breast cancer who have received chemotherapy for metastatic disease or disease recurrence during or within 6 months of completing adjuvant chemotherapy
  • Patient support services
  • Enhertu Patient Savings Program
    833-364-3788

    Enhertu Patient Assistance Program
    833-364-3788


    Drug name (generic name)
  • Faslodex (fulvestrant)
  • Drug company
  • AstraZeneca
  • Indication
  • First-line treatment of HRpositive, HER2-negative advanced breast cancer in postmenopausal women who have not received endocrine therapy

    HR-positive metastatic breast cancer in postmenopausal women, after anti-estrogen therapy

    HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with Ibrance or with Verzenio
  • Patient support services
  • FASLODEX Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    844-275-2360



    Drug name (generic name)
  • Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) Injection
  • Drug company
  • Genentech
  • Indications
  • Adjuvant treatment of HER2-positive breast cancer, in combination with chemotherapy, or alone after multiple anthracycline-based therapies

    Treatment of HER2-positive metastatic breast cancer, after 1 or more chemotherapies for metastatic disease
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Ibrance (palbociclib) Capsules/Tablets
  • Drug company
  • Pfizer
  • Indications
  • Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor as initial endocrine-based therapy, in postmenopausal women, or in men

    Treatment of HR-positive, HER2-negative advanced or metastatic breast cancer, in combination with fulvestrant, in adults whose disease progressed after endocrine therapy
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Ixempra (ixabepilone)
  • Drug company
  • R-Pharm US
  • Indications
  • Metastatic or locally advanced breast cancer, in combination with Xeloda

    Metastatic or locally advanced breast cancer, after failure of an anthracycline, a taxane, and Xeloda
  • Patient support services
  • R-Pharm US Access + Support Program
    855-991-7277

    Drug name (generic name)
  • Kadcyla (ado-trastuzumab emtansine)
  • Drug company
  • Genentech
  • Indication
  • HER2-positive metastatic breast cancer, after Herceptin and/or a taxane

    Adjuvant treatment of HER2-positive early breast cancer in patients with residual invasive disease, after neoadjuvant taxane and trastuzumab-based treatment
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • Treatment, in combination with chemotherapy, of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors express PD-L1, as determined by an FDA-approved test

    Treatment of patients with highrisk, early-stage, triple-negative breast cancer, in combination with chemotherapy as neoadjuvant treatment, and then continued alone as adjuvant treatment after surgery
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932


    Drug name (generic name)
  • Lynparza (olaparib) Capsules/Tablets
  • Drug company
  • AstraZeneca
  • Indications
  • Treatment of deleterious or suspected deleterious germline BRCA mutation-positive, HER2- negative metastatic breast cancer, after chemotherapy

    Adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Patients must be selected for therapy based on an FDA-approved companion diagnostic for olaparib
  • Patient support services
  • Lynparza Co-pay Savings Program
    844-275-2360

    AZ&Me Prescription Savings Program
    800-292-6363

    Drug name (generic name)
  • Margenza (margetuximab-cmkb) Injection
  • Drug company
  • MacroGenics
  • Indications
  • Treatment, in combination with chemotherapy, of adults with metastatic HER2-positive breast cancer who have received 2 or more previous anti-HER2 regimens, at least 1 of which was for metastatic disease
  • Patient support services
  • Margenza Copay Assistance Program
    844-633-6469

    Margenza Patient Assistance Program
    844-633-6469



    Drug name (generic name)
  • Ontruzant (trastuzumab-dttb) Injection
  • Drug company
  • Organon
  • Indications
  • First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer

    Treatment of HER2- overexpressing breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
  • Patient support services
  • Organon Co-pay Assistance Program
    844-326-2986

    Organon Patient Assistance Program
    844-326-2986

    Drug name (generic name)
  • Perjeta (pertuzumab)
  • Drug company
  • Genentech
  • Indications
  • HER2-positive metastatic breast cancer, in combination with Herceptin and Taxotere

    Neoadjuvant treatment for HER2-positive, locally advanced, inflammatory, or early-stage breast cancer, in combination with Herceptin and Taxotere
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Phesgo (pertuzumab, trastuzumab + hyaluronidase-zzxf) Injection
  • Drug company
  • Genentech
  • Indications
  • Neoadjuvant treatment, in combination with chemotherapy, of patients with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer

    Adjuvant treatment of patients with HER2-positive early-stage breast cancer at high risk of recurrence

    Treatment, in combination with docetaxel, of patients with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331



    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indications
  • Treatment, in combination with Abraxane, of unresectable, locally advanced or metastatic triple-negative breast cancer expressing PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Trazimera (trastuzumab-qyyp)
  • Drug company
  • Pfizer
  • Indications
  • Adjuvant treatment, in combination with various chemotherapy regimens, of patients with HER2-overexpressing node-positive or node-negative breast cancer

    Treatment of HER2-overexpressing breast cancer as a single agent, after anthracycline-based therapy

    First-line treatment, in combination with paclitaxel, of HER2-overexpressing metastatic breast cancer

    Treatment of HER2-overexpressing metastatic breast cancer in patients who have received 1 or more chemotherapy regimens for metastatic disease
  • Patient support services
  • Pfizer Oncology Together Co-Pay Savings Program
    877-744-5675

    Pfizer Patient Assistance Program
    877-744-5675

    Drug name (generic name)
  • Trodelvy (sacituzumab govitecan-hziy) Injection
  • Drug company
  • Gilead
  • Indications
  • Treatment of adults with metastatic triple-negative breast cancer who have received at least 2 previous therapies for metastatic disease
  • Patient support services
  • Trodelvy Savings Program
    844-876-3358

    Gilead Patient Assistance Program
    844-876-3358

    Drug name (generic name)
  • Tukysa (tucatinib) Tablets
  • Drug company
  • Seagen
  • Indications
  • Treatment of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received 1 or more previous anti-HER2 regimens for metastatic disease
  • Patient support services
  • Commercial Out-of-Pocket Assistance Program
    855-473-2873

    Patient Assistance Program
    855-473-2873

    Drug name (generic name)
  • Tykerb (lapatinib) Tablets
  • Drug company
  • Novartis
  • Indications
  • Advanced or metastatic breast cancer overexpressing HER2, in combination with Xeloda, after an anthracycline, a taxane, and Herceptin

    Postmenopausal, HR-positive metastatic breast cancer overexpressing HER2, in combination with Femara
  • Patient support services
  • Novartis Oncology Universal Co-pay Program
    877-577-7756

    Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Verzenio (abemaciclib) Tablets
  • Drug company
  • Eli Lilly
  • Indication
  • Adjuvant treatment, in combination with endocrine therapy, tase inhibitor) of adults with HR-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score at least 20%, as determined by an FDA-approved test

    As initial endocrine-based treatment, in combination with an aromatase inhibitor, of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer

    Treatment, in combination with fulvestrant, of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after endocrine therapy

    Treatment (alone) of adults with HR-positive, HER2-negative advanced or metastatic breast cancer that progressed after endocrine therapy and before chemotherapy in the metastatic setting
  • Patient support services
  • Verzenio Continuous Care Program
    844-837-9364

    Verzenio Savings Card
    844-837-9364

    Drug name (generic name)
  • Xeloda (capecitabine) Tablets
  • Drug company
  • Genentech
  • Indications
  • Metastatic breast cancer, in combination with Taxotere, after failure of anthracyclinecontaining therapy
  • Patient support services
  • Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Zoladex (goserelin) Implant
  • Drug company
  • TerSera Therapeutics
  • Indication
  • Palliative treatment, in combination with flutamide, of premenopausal or perimenopausal women with advanced breast cancer
  • Patient support services
  • Zoladex Copay Card
    844-864-3014

    Zoladex Patient Assistance Program
    855-686-8725
Last modified: March 9, 2023

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to Conquer: the journey informed

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests